Dihydroergocornine

Identification

Name
Dihydroergocornine
Accession Number
DB11273
Type
Small Molecule
Groups
Approved
Description

Dihydroergocornine is one of the dihydrogenated ergot compounds that present very large hypotensive effects.[1] It is an artificial derivative of the crude extract of ergot and later purified, ergocornine.[2] The formation of dihydroergocornine implies the hydrogenation of the double bonds in the lysergic acid.[3] Dihydroergocornine presents a formula of 9,10 alpha-dihydro-12'-hydroxy-2',5'alpha-bis(1-methylethyl)-ergotaman-3',6',18-trione.[7] It is found as one of the components in the ergoloid mesylate mixture. To know more about this mixture please refer to Ergoloid mesylate

Structure
Thumb
Synonyms
  • 9,10-dihydroergocornine
Product Ingredients
IngredientUNIICASInChI Key
Dihydroergocornine mesylate42RX8KPW2929261-94-7UOOWRCRLTSXSAV-GSZJWLEYSA-N
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Ergoloid MesylatesDihydroergocornine mesylate (0.333 mg/1) + Dihydro-alpha-ergocryptine mesylate (0.222 mg/1) + Dihydroergocristine mesylate (0.333 mg/1) + Epicriptine mesilate (0.111 mg/1)TabletOralCarilion Materials Management1991-10-31Not applicableUs
Ergoloid MesylatesDihydroergocornine mesylate (0.333 mg/1) + Dihydro-alpha-ergocryptine mesylate (0.222 mg/1) + Dihydroergocristine mesylate (0.333 mg/1) + Epicriptine mesilate (0.111 mg/1)TabletOralSun Pharmaceutical Industries Limited1991-10-31Not applicableUs
Categories
UNII
IK4C1OC8NE
CAS number
25447-65-8
Weight
Average: 563.699
Monoisotopic: 563.31076944
Chemical Formula
C31H41N5O5
InChI Key
SEALOBQTUQIVGU-QNIJNHAOSA-N
InChI
InChI=1S/C31H41N5O5/c1-16(2)26-28(38)35-11-7-10-24(35)31(40)36(26)29(39)30(41-31,17(3)4)33-27(37)19-12-21-20-8-6-9-22-25(20)18(14-32-22)13-23(21)34(5)15-19/h6,8-9,14,16-17,19,21,23-24,26,32,40H,7,10-13,15H2,1-5H3,(H,33,37)/t19-,21-,23-,24+,26+,30-,31+/m1/s1
IUPAC Name
(2R,4R,7R)-N-[(1S,2S,4R,7S)-2-hydroxy-5,8-dioxo-4,7-bis(propan-2-yl)-3-oxa-6,9-diazatricyclo[7.3.0.0^{2,6}]dodecan-4-yl]-6-methyl-6,11-diazatetracyclo[7.6.1.0^{2,7}.0^{12,16}]hexadeca-1(16),9,12,14-tetraene-4-carboxamide
SMILES
[H][C@@]12CCCN1C(=O)[C@H](C(C)C)N1C(=O)[C@](NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)[C@@]4([H])C3)(O[C@@]21O)C(C)C

Pharmacology

Indication

To know more about the approved indications please visit Ergoloid mesylate

Structured Indications
Not Available
Pharmacodynamics

It is reported that dihydroergocornine administration, in non-toxic doses, presents sympatholytic and hypotensive properties which are observed as a significantly decreased mean arterial pressure.[2] In the brain, the activity of dihydroergocornine was observed as a decrease in cerebral blood flow, cerebral vascular resistance and oxygen uptake. The effect in the brain seems to allow a cerebral metabolic homeostasis.[1] To know more about the pharmacology please visit Ergoloid mesylate

Mechanism of action

The mechanism of action by which dihydroergocornine exerts its effects are not entirely defined. However, it is reported that dihydroergocornine has central and peripheral effects. The fall in blood pressure seems to be related to the stimulation of the vasodilator center.[4] It has been demonstrated that dihydroergocornine possesses potent adrenolytic and sympathicolytic actions.[5] The effect of dihydroergocornine is related to the inhibitory effect against the serotonin and noradrenaline receptors in which dihydroergocornine seems to be very potent against a stimulation-induced noradrenaline overflow. It also presents a stimulatory effect in arterial and venous smooth muscle when administered at slightly higher concentrations than the necessary for the inhibitory effect.[6]

TargetActionsOrganism
ASerotonin Receptors
antagonist
agonist
Human
ABeta adrenergic receptor
antagonist
agonist
Human
AAlpha adrenergic receptor
antagonist
agonist
Human
Absorption

Dihydroergocornine absorption in man after oral administration is very rapid when compared to the mixture or most of the components. The time to reach maximum plasma concentration or 0.57 ng-eq/ml is 1.4 hours. It presents an absorption half-life of 0.32 hours. The absorption percentage is of about 25% which corresponds to the registered absorption presented in the ergoloid mixture.[8] To know more about the pharmacokinetics please visit Ergoloid mesylate.

Volume of distribution

To know more about the pharmacokinetics please visit Ergoloid mesylate.

Protein binding

To know more about the pharmacokinetics please visit Ergoloid mesylate.

Metabolism

The biotransformation of dihydroergocornine occurs via oxidation and cleavage of the proline in the peptide portion of the molecule as well as by the splitting of the amide bond yielding dihydrolysergic acid amide. Some of the derivate metabolites retain the essential ring structure of the ergot alkaloid.[9] To know more about the pharmacokinetics please visit Ergoloid mesylate.

Route of elimination

When orally administered, dihydroergocornine is almost completely eliminated via feces. The urinary secretion accounts only for 2.5% of the administered dose. On the other hand, when administered intravenously, the renal excretion can account for approximately 10% of the administered dose.[8] To know more about the pharmacokinetics please visit Ergoloid mesylate.

Half life

To know more about the pharmacokinetics please visit Ergoloid mesylate.

Clearance

No pharmacokinetic related to the clearance rate was found in current literature.

Toxicity

Dihydroergocornine effect on fertility was tested in preclinical studies. The reported effect was a decreased weight gain in neonates.[10] Overdosing has also been reported to present effects of fall of blood pressure and a decrease in heart rate to 13 beats per minute.[4] To know more about the pharmacokinetics please visit Ergoloid mesylate.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AcetaminophenThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Acetaminophen.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Acetazolamide.Approved, Vet Approved
Acetyl sulfisoxazoleThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Acetyl sulfisoxazole.Approved, Vet Approved
AldesleukinThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Aldesleukin.Approved
AlprazolamThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Alprazolam.Approved, Illicit, Investigational
AmbroxolThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Ambroxol.Approved, Investigational
AmlodipineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Amlodipine.Approved
AmprenavirThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Amprenavir.Approved, Investigational
AnastrozoleThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Anastrozole.Approved, Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Antipyrine.Approved, Investigational
Arsenic trioxideThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Arsenic trioxide.Approved, Investigational
AstemizoleThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Astemizole.Approved, Withdrawn
AtazanavirThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Atazanavir.Approved, Investigational
AtomoxetineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Atomoxetine.Approved
AtorvastatinThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Atorvastatin.Approved
AzelastineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Azelastine.Approved
AzithromycinThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Azithromycin.Approved
BetamethasoneThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Betamethasone.Approved, Vet Approved
BicalutamideThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Bicalutamide.Approved
BifonazoleThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Bifonazole.Approved, Investigational
BoceprevirThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Boceprevir.Approved, Withdrawn
BortezomibThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Bortezomib.Approved, Investigational
Brentuximab vedotinThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Brentuximab vedotin.Approved, Investigational
BromocriptineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Bromocriptine.Approved, Investigational
BuprenorphineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
CabergolineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Cabergoline.Approved
CaffeineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Caffeine.Approved
CapsaicinThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Capsaicin.Approved
CaspofunginThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Caspofungin.Approved
CeritinibThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Ceritinib.Approved
CerivastatinThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Cerivastatin.Approved, Withdrawn
ChloramphenicolThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Chloramphenicol.Approved, Vet Approved
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Chlorzoxazone.Approved
CilostazolThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Cilostazol.Approved, Investigational
Cimicifuga racemosaThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Cimicifuga racemosa.Approved, Experimental
CiprofloxacinThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Ciprofloxacin.Approved, Investigational
CirazolineDihydroergocornine may increase the hypertensive activities of Cirazoline.Experimental
CisaprideThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Cisapride.Approved, Investigational, Withdrawn
ClarithromycinThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Clarithromycin.Approved
ClemastineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Clemastine.Approved, Investigational
ClindamycinThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Clindamycin.Approved, Vet Approved
ClofazimineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Clofazimine.Approved, Investigational
ClomifeneThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Clomifene.Approved, Investigational
ClotiazepamThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Clotiazepam.Approved, Illicit
ClotrimazoleThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Clotrimazole.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Clozapine.Approved
CobicistatThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Cobicistat.Approved
CocaineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Cocaine.Approved, Illicit
ColchicineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Colchicine.Approved
ConivaptanThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Conivaptan.Approved, Investigational
Cortisone acetateThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Cortisone acetate.Approved, Investigational
CrizotinibThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Crizotinib.Approved
CyclophosphamideThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Cyclophosphamide.Approved, Investigational
CyclosporineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Cyclosporine.Approved, Investigational, Vet Approved
DalfopristinThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Dalfopristin.Approved
DanazolThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Danazol.Approved
DarunavirThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Darunavir.Approved
DasatinibThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Dasatinib.Approved, Investigational
DaunorubicinThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Daunorubicin.Approved
DelavirdineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Delavirdine.Approved
DesipramineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Desipramine.Approved, Investigational
DexamethasoneThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Dexamethasone.Approved, Investigational, Vet Approved
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Dextropropoxyphene.Approved, Illicit, Investigational, Withdrawn
DiazepamThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Diazepam.Approved, Illicit, Investigational, Vet Approved
DiethylstilbestrolThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Diethylstilbestrol.Approved, Investigational
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Dihydroergotamine.Approved, Investigational
Dimethyl sulfoxideThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Dimethyl sulfoxide.Approved, Vet Approved
DocetaxelThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Docetaxel.Approved, Investigational
DoxorubicinThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Doxorubicin.Approved, Investigational
DoxycyclineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Dronedarone.Approved
EconazoleThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Econazole.Approved
EfavirenzThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Efavirenz.Approved, Investigational
EfonidipineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Efonidipine.Approved, Investigational
ElbasvirThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Elbasvir.Approved
EnasidenibThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Enasidenib.Approved, Investigational
EpinephrineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Epinephrine.Approved, Vet Approved
ErgonovineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Ergonovine.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Ergotamine.Approved
ErythromycinThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Erythromycin.Approved, Investigational, Vet Approved
EthanolThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Ethanol.Approved
EtoposideThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Etoposide.Approved
EtoricoxibThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Etoricoxib.Approved, Investigational
EzetimibeThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Ezetimibe.Approved
FelodipineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Felodipine.Approved, Investigational
FentanylThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FluoxetineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Fluoxetine.Approved, Vet Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Fluticasone propionate.Approved
FluvastatinThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Fluvastatin.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Fosamprenavir.Approved
FosaprepitantThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Fosaprepitant.Approved
FosnetupitantThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Fosnetupitant.Approved
GemfibrozilThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Gemfibrozil.Approved
GlyburideThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Glyburide.Approved
Glycerol PhenylbutyrateThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Glycerol Phenylbutyrate.Approved
HaloperidolThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Haloperidol.Approved
HistamineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Histamine.Approved, Investigational
HydralazineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Hydralazine.Approved
HydrocortisoneThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Hydrocortisone.Approved, Vet Approved
IdelalisibThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Idelalisib.Approved
IfosfamideThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Ifosfamide.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Iloperidone.Approved
ImatinibThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Imatinib.Approved
IndinavirThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Indinavir.Approved
IndisulamThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Indisulam.Investigational
IrbesartanThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Irbesartan.Approved, Investigational
IrinotecanThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Irinotecan.Approved, Investigational
IsavuconazoleThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Isavuconazole.Approved, Investigational
IsavuconazoniumThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Isavuconazonium.Approved, Investigational
IsoniazidThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Isoniazid.Approved, Investigational
IsradipineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Isradipine.Approved, Investigational
ItraconazoleThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Itraconazole.Approved, Investigational
IvacaftorThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Ivacaftor.Approved
JosamycinThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Josamycin.Approved, Investigational
KetazolamThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Ketazolam.Approved
KetoconazoleThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Ketoconazole.Approved, Investigational
LansoprazoleThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Lansoprazole.Approved, Investigational
LapatinibThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Lapatinib.Approved, Investigational
LercanidipineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Lercanidipine.Approved, Investigational
LevofloxacinThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Levofloxacin.Approved, Investigational
LevosalbutamolThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Levosalbutamol.Approved, Investigational
LidocaineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Lidocaine.Approved, Vet Approved
LinagliptinThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Linagliptin.Approved
LomitapideThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Lomitapide.Approved, Investigational
LomustineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Lomustine.Approved, Investigational
LopinavirThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Lopinavir.Approved
LoratadineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Loratadine.Approved, Investigational
LosartanThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Losartan.Approved
LovastatinThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Lovastatin.Approved, Investigational
LuliconazoleThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Luliconazole.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Lurasidone.Approved, Investigational
ManidipineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Manidipine.Approved, Investigational
MefloquineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Mefloquine.Approved, Investigational
MephentermineDihydroergocornine may increase the hypertensive activities of Mephentermine.Approved
MequitazineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Mequitazine.Approved
MetaraminolDihydroergocornine may increase the hypertensive activities of Metaraminol.Approved, Investigational
MethadoneThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Methadone.Approved
MethazolamideThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Methazolamide.Approved
MethimazoleThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Methimazole.Approved
MethoxamineDihydroergocornine may increase the hypertensive activities of Methoxamine.Approved, Investigational
MethylergometrineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Methylergometrine.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Methylprednisolone.Approved, Vet Approved
MetronidazoleThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Metronidazole.Approved
MetyraponeThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Metyrapone.Approved, Investigational
MibefradilThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Mibefradil.Investigational, Withdrawn
MiconazoleThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Miconazole.Approved, Investigational, Vet Approved
MidazolamThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Midazolam.Approved, Illicit
MidodrineDihydroergocornine may increase the hypertensive activities of Midodrine.Approved
MifepristoneThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Mifepristone.Approved, Investigational
MirtazapineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Mirtazapine.Approved
MitoxantroneThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Mitoxantrone.Approved, Investigational
ModafinilThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Modafinil.Approved, Investigational
NabiloneThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Nabilone.Approved, Investigational
NelfinavirThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Nelfinavir.Approved
NetupitantThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Netupitant.Approved, Investigational
NevirapineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Nevirapine.Approved
NicardipineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Nicardipine.Approved, Investigational
NicotinamideThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Nicotinamide.Approved, Investigational
NifedipineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Nifedipine.Approved
NilotinibThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Nilotinib.Approved, Investigational
NilvadipineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Nilvadipine.Approved, Investigational
NisoldipineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Nisoldipine.Approved
NitrendipineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Nitrendipine.Approved, Investigational
Nitric OxideThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Nitric Oxide.Approved
NitroglycerinThe bioavailability of Dihydroergocornine can be increased when combined with Nitroglycerin.Approved, Investigational
NorfloxacinThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Norfloxacin.Approved
NoscapineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Noscapine.Investigational
OlanzapineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Olanzapine.Approved, Investigational
OlaparibThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Olaparib.Approved
OmeprazoleThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Omeprazole.Approved, Investigational, Vet Approved
OxybutyninThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Oxybutynin.Approved, Investigational
OxymetholoneThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Oxymetholone.Approved, Illicit
PaclitaxelThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Paclitaxel.Approved, Vet Approved
PalbociclibThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Palbociclib.Approved, Investigational
ParamethasoneThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Paramethasone.Approved
PazopanibThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Pazopanib.Approved
Peppermint oilThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Peppermint oil.Approved, Investigational
PergolideThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Pergolide.Approved, Investigational, Vet Approved, Withdrawn
PhenelzineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Phenelzine.Approved
PhenylephrineDihydroergocornine may increase the hypertensive activities of Phenylephrine.Approved
PilocarpineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Pilocarpine.Approved, Investigational
PimozideThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Pimozide.Approved
PiperaquineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Piperaquine.Approved, Investigational
PosaconazoleThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Posaconazole.Approved, Investigational, Vet Approved
PravastatinThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Pravastatin.Approved
PrednisoloneThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Prednisone.Approved, Vet Approved
PrimaquineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Primaquine.Approved
ProgesteroneThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Progesterone.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Propofol.Approved, Investigational, Vet Approved
QuinidineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Quinidine.Approved, Investigational
QuinineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Quinine.Approved
QuinupristinThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Quinupristin.Approved
RabeprazoleThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Rabeprazole.Approved, Investigational
RaloxifeneThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Raloxifene.Approved, Investigational
RanitidineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Ranitidine.Approved
RanolazineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Ranolazine.Approved, Investigational
RegorafenibThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Regorafenib.Approved
RepaglinideThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Repaglinide.Approved, Investigational
ResveratrolThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Resveratrol.Approved, Experimental, Investigational
RilpivirineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Rilpivirine.Approved
RisperidoneThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Risperidone.Approved, Investigational
RitonavirThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Ritonavir.Approved, Investigational
RivastigmineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Rivastigmine.Approved, Investigational
RolitetracyclineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Rolitetracycline.Approved
RosuvastatinThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Rosuvastatin.Approved
RoxithromycinThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Roxithromycin.Approved, Investigational, Withdrawn
RucaparibThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Rucaparib.Approved, Investigational
RutinThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Rutin.Experimental, Investigational
SalbutamolThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Salbutamol.Approved, Vet Approved
SaquinavirThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Saquinavir.Approved, Investigational
SarilumabThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Sarilumab.Approved, Investigational
SertralineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Sertraline.Approved
SildenafilThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Sildenafil.Approved, Investigational
SimeprevirThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Simeprevir.Approved
SimvastatinThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Simvastatin.Approved
SirolimusThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Sirolimus.Approved, Investigational
SitaxentanThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Sitaxentan.Approved, Investigational, Withdrawn
SorafenibThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Sorafenib.Approved, Investigational
StiripentolThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Stiripentol.Approved
SulfamethoxazoleThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Sulfamethoxazole.Approved
SulfanilamideThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Sulfanilamide.Approved
SulfinpyrazoneThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Sulfinpyrazone.Approved
SulfisoxazoleThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Sulfisoxazole.Approved, Vet Approved
TacrolimusThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Tacrolimus.Approved, Investigational
TadalafilThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Tadalafil.Approved, Investigational
TamoxifenThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Tamoxifen.Approved
TelaprevirThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Telaprevir.Approved, Withdrawn
TelithromycinThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Telithromycin.Approved
TemsirolimusThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Temsirolimus.Approved
TeniposideThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Teniposide.Approved
TerfenadineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Terfenadine.Approved, Withdrawn
TesmilifeneThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Tesmilifene.Investigational
TestosteroneThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Testosterone.Approved, Investigational
Testosterone cypionateThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Testosterone cypionate.Approved
Testosterone enanthateThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Testosterone enanthate.Approved
Testosterone undecanoateThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Testosterone undecanoate.Approved, Investigational
TetracyclineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Tetracycline.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Thiopental.Approved, Vet Approved
TicagrelorThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Ticagrelor.Approved
TiclopidineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Ticlopidine.Approved
TioconazoleThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Tioconazole.Approved
TipranavirThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Tipranavir.Approved, Investigational
TofisopamThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Tofisopam.Approved
TopiroxostatThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Topiroxostat.Approved, Investigational
TopotecanThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Topotecan.Approved, Investigational
TramadolThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Tramadol.Approved, Investigational
TranylcypromineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Tranylcypromine.Approved, Investigational
TroglitazoneThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Troglitazone.Investigational, Withdrawn
TroleandomycinThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Troleandomycin.Approved
Valproic AcidThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Valproic Acid.Approved, Investigational
VenlafaxineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Venlafaxine.Approved
VinblastineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Vinblastine.Approved
VincristineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Vincristine.Approved, Investigational
VinorelbineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Vinorelbine.Approved, Investigational
VoriconazoleThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Voriconazole.Approved, Investigational
ZafirlukastThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Zafirlukast.Approved, Investigational
ZiprasidoneThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Ziprasidone.Approved
ZucapsaicinThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Zucapsaicin.Approved, Investigational
Food Interactions
Not Available

References

General References
  1. HAFKENSCHIEL JH, CRUMPTON CW, MOYER JH, JEFFERS WA, FISHEL HANLEY B, CONLIN HARNED S: The effects of dihydroergocornine on the cerebral circulation of patients with essential hypertension. J Clin Invest. 1950 Apr;29(4):408-11. doi: 10.1172/JCI102273. [PubMed:15415441]
  2. FREIS ED, STANTON JR, et al.: The hemodynamic effects of hypotensive drugs in man; dihydroergocornine. J Clin Invest. 1949 Nov;28(6 Pt 2):1387-1402. doi: 10.1172/JCI102204. [PubMed:15395942]
  3. Bercel NA: TREATMENT OF MIGRAINE-Results with Dihydroergocornine Methanesulfonate (DHO-180) and Other Ergot Derivatives. Calif Med. 1950 Apr;72(4):234-8. [PubMed:18731688]
  4. Hayes DW, Wakim KG, Horton BT, Peters GA: THE EFFECTS OF DIHYDROERGOCORNINE ON THE CIRCULATION IN THE EXTREMITIES OF MAN. J Clin Invest. 1949 Jul;28(4):615-20. doi: 10.1172/JCI102111. [PubMed:16695718]
  5. FLORMAN AL, FISCHER AE, MOLOSHOK RE: An evaluation of the mumps skin-test in pediatric practice. Bull N Y Acad Med. 1949 Jul;25(7):441. [PubMed:18152249]
  6. Muller-Schweinitzer E: Actions of co-dergocrine mesylate and its components at vascular smooth muscle. Naunyn Schmiedebergs Arch Pharmacol. 1982 Feb;318(3):225-33. [PubMed:7063048]
  7. Florey K. (1978). Analytical profiles of drug substances (7th ed.). Academic Press. [ISBN:0-12-260807-0]
  8. Berde B. and Schild H. (1978). Ergot alkaloids and related compounds. Springer-Verlag. [ISBN:978-3-642-66777-0]
  9. Barceloux D. (2008). Medical toxicology of natural substances. Wiley. [ISBN:978-0-470-33447-4]
  10. Preston S. (1917). Endocrinology. Williams & Wilkins Co..
External Links
ChemSpider
147720
ChEBI
59909
ChEMBL
CHEMBL2365712
Wikipedia
Dihydroergocornine

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
TabletOral
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)187 ºCFlorey K. Analytical profiles of drug substances. 1978.
boiling point (°C)DecomposesFlorey K. Analytical profiles of drug substances. 1978.
logP2.33ChemSrc
Predicted Properties
PropertyValueSource
Water Solubility0.402 mg/mLALOGPS
logP3.1ALOGPS
logP3.06ChemAxon
logS-3.2ALOGPS
pKa (Strongest Acidic)9.71ChemAxon
pKa (Strongest Basic)8.39ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area118.21 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity152.66 m3·mol-1ChemAxon
Polarizability62 Å3ChemAxon
Number of Rings7ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as ergopeptines. These are ergoline derivatives that contain a tripeptide structure attached to the basic ergoline ring in the same location as the amide group of the lysergic acid derivatives.
Kingdom
Organic compounds
Super Class
Alkaloids and derivatives
Class
Ergoline and derivatives
Sub Class
Lysergic acids and derivatives
Direct Parent
Ergopeptines
Alternative Parents
Hybrid peptides / Dipeptides / Lysergamides / Indoloquinolines / Benzoquinolines / Quinoline-3-carboxamides / Pyrroloquinolines / N-acyl-alpha amino acids and derivatives / 3-alkylindoles / Piperidinecarboxamides
show 20 more
Substituents
Ergopeptine / Hybrid peptide / Alpha-dipeptide / Lysergic acid amide / Indoloquinoline / Benzoquinoline / Quinoline-3-carboxamide / N-acyl-alpha amino acid or derivatives / Pyrroloquinoline / Alpha-amino acid or derivatives
show 41 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
ergot alkaloid (CHEBI:59909)

Targets

Kind
Protein group
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
Agonist
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances. Ligand binding causes a conformation change that triggers...

Components:
References
  1. Muller-Schweinitzer E: Actions of co-dergocrine mesylate and its components at vascular smooth muscle. Naunyn Schmiedebergs Arch Pharmacol. 1982 Feb;318(3):225-33. [PubMed:7063048]
Kind
Protein group
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
Agonist
General Function
Receptor signaling protein activity
Specific Function
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. This receptor binds epinephrine and norepinephrine with approximately e...

Components:
References
  1. Muller-Schweinitzer E: Actions of co-dergocrine mesylate and its components at vascular smooth muscle. Naunyn Schmiedebergs Arch Pharmacol. 1982 Feb;318(3):225-33. [PubMed:7063048]
Kind
Protein group
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
Agonist
General Function
Protein heterodimerization activity
Specific Function
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...

Components:
References
  1. Muller-Schweinitzer E: Actions of co-dergocrine mesylate and its components at vascular smooth muscle. Naunyn Schmiedebergs Arch Pharmacol. 1982 Feb;318(3):225-33. [PubMed:7063048]

Drug created on December 03, 2015 09:51 / Updated on May 08, 2018 12:10